The role of CA 15.3 assays in breast cancer;Place actuelle des dosages du CA 15.3 dans le cancer du sein

Immuno-Analyse et Biologie Specialisee

Volumn 19, Issue 5 SPEC. ISS., 2004, Pages 274-278

  De La Lande, B ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Breast cancer; CA 15.3; Cancer du sein

Indexed keywords

CA 15-3 ANTIGEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; IMMUNOASSAY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 4744351494     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2004.06.008     Document Type: Article

References (16)

1. American Society of Clinical Oncology Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer J. Clin. Oncol. 16 1998 793 795
2. R.C. Bast, P. Radvin, D.F. Hayes, S. Bates, H. Fritsche, and J. Jessup 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J. Clin. Oncol. 19 2001 1865 1878
3. J.P. Basuyau, M.P. Blanc-Vincent, A. Daver, L. Deneux, N. Eche, and G. Gory-Delabaere Standards Options et Recommandations (SOR): marqueurs tumoraux du cancer du sein Bull. Cancer 87 2000 723 737
4. C. Boccara, J.P. Basuyau, P. Brunelle, P. Bastit, M. Berry, and A. Chevrier Apport du CA 15.3 en cancérologie mammaire Immunoanal. Biol. Spec. 13 1998 19 25
5. R. Colomer, A. Ruibal, and L. Salvador Circulating tumor marker levels in advanced breast carcinoma with the extend of metastatic disease Cancer 64 1989 1674 1681
6. B. De La Lande, K. Hacene, J.L. Floiras, N. Alatrakchi, and M.F. Pichon Prognostic value of CA 15.3 kinetics for metastatic breast cancer Int. J. Biol. Markers 17 2002 231 238
7. M. Gion, P. Boracchi, R. Dittadi, E. Biganzoli, L. Peloso, and R. Mione Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game Eur. J. Cancer 38 2002 1181 1188
8. S. Giordano, A.U. Buzdar, T.L. Smith, S.W. Kau, Y. Yang, and G.N. Hortobagyi Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000 Cancer 100 2004 44 52
9. W. Jager The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements Eur. J. Cancer Prev. 2 suppl 3 1993 133 139
10. N. Mlika-Cabanne, and D. Bellet Au nom du groupe de travail réuni par l'ANAES Recommandations et Références médicales. Marqueurs sériques dans les cancers du sein et les cancers colo-rectaux Gastroenterol. Clin. Biol. 22 1998 442 457
11. P. Nicolini, P. Ferrari, A. Sagripanti, and A. Carpi The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy Br. J. Cancer 79 1999 1443 1447
12. P. Nicolini, A. Carpi, C. Michelassi, C. Spinelli, M. Conte, and P. Miccoli Tumour marker guided salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study Biomed. Pharmacother. 57 2003 452 459
13. R. Nishimura, K. Nagao, H. Miyayama, M. Matsuda, K. Baba, and Y. Matsuoka Elevated serum CA 15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer Breast Cancer 10 2003 220 227
14. S.G. Schering, F. Sherry, E.W. McDermott, N.J. O'Higgins, and M.J. Duffy Preoperative CA 15.3 concentrations predict outcome of patients with breast carcinoma Cancer 83 1998 2521 2527
15. M. Tampellini, A. Berruti, G. Gorzegno, R. Bitossi, A. Bottini, and A. Durando Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse Tumour Biol. 22 2001 367 373
16. Working group on tumor marker criteria, International Society Of Biological Markers Tumor Biol. 11 1990 287 288